Tyra Biosciences price target lowered to $28 from $29 at BofA

BofA analyst Jason Zemansky lowered the firm’s price target on Tyra Biosciences (TYRA) to $28 from $29 and keeps a Buy rating on the shares. Tyra’s Q4 update was “altogether uneventful,” says the analyst, who attributes the trimmed target to updating the firm’s model to incorporate the latest financials and timelines. The firm argue the recent weakness in shares has “more to do with macro dynamics than anything specific about the company’s portfolio” and with regulators supportive of advancing ‘300 – along with the optionality of the pipeline with ‘200 and ‘430 advancing – BofA continues to “see reasons to like the story.”